Clinical trial
Named Patient or Compassionate Use for Treatment Use of ATB200/AT2221 for Patients With Pompe Disease
Name
ATB200-11
Description
This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.
Trial arms
Treatment
ATB200
AT2221
Size
-1
Eligibility criteria
Inclusion Criteria:
1. Subject must have a diagnosis of Pompe disease based on documentation of one of the following:
1. deficiency of GAA enzyme
2. GAA genotyping
2. Patient does not currently qualify for an Amicus sponsored on-going clinical trial or is declining on currently approved ERT (e.g. Myozyme)
3. The patient must be willing to receive treatment with ATB200/AT2221 via this program, which includes signing an authorization form for sharing clinical data with Amicus Therapeutics, and its agent Early Access Care LLC.
Exclusion Criteria:
1. Patient, whether male or female, is planning to conceive a child during the treatment program.
2. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221
3. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with or adversely impact protocol requirements.
4. Patient has received any gene therapy at any time.
5. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb, or Volibo)
Protocol
{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 1, 'expandedAccessTypes': {'individual': True}}
Updated at
2023-07-27
1 organization
2 products
1 indication
Organization
Amicus TherapeuticsProduct
AT2221Indication
Pompe DiseaseProduct
ATB200